Possible uptrend continuation into March 12th earnings.
*320% expected quarterly revenue.
*50% decrease in short interest.
*NDA filing on phase 3 data for Baxdela in 1H 2019.
*19% volume increase in past 4 days.
Entry Points - 1.32 - 1.45
Price Targets - 1.72---2.00---2.26---2.43
Stop-Loss - 1.25
Melinta Therapeutics Company Profile
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP.
*320% expected quarterly revenue.
*50% decrease in short interest.
*NDA filing on phase 3 data for Baxdela in 1H 2019.
*19% volume increase in past 4 days.
Entry Points - 1.32 - 1.45
Price Targets - 1.72---2.00---2.26---2.43
Stop-Loss - 1.25
Melinta Therapeutics Company Profile
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP.